Medicine and Dentistry
Doxorubicin
100%
Cardiotoxicity
100%
Patient
72%
Single Nucleotide Polymorphism
54%
Expression Quantitative Trait Locus
36%
Cardiomyocyte
27%
Chemotherapeutic Agent
27%
Drug
27%
Pediatrics Patient
18%
Induced Pluripotent Stem Cell
18%
Gene Expression
18%
Therapeutic Procedure
18%
Experience
18%
Genome Wide Association Study
18%
Gene
18%
Heart Failure
9%
Leukemia
9%
In Vitro
9%
Clustered Regularly Interspaced Short Palindromic Repeat
9%
Drug Response
9%
Cas9
9%
Rigor
9%
Lymphoblastoid Cell Line
9%
Quantitative Trait Locus Mapping
9%
Sarcoma
9%
Adverse Drug Reaction
9%
Phenotype
9%
Lymphoma
9%
Solid Malignant Neoplasm
9%
Cells
9%
Combination Therapy
9%
Base
9%
Association
9%
Predictor
9%
Assay
9%
Biopsy
9%
Genotype
9%
Organ
9%
Chemotherapy
9%
INIS
doxorubicin
100%
validation
100%
patients
90%
nucleotides
54%
humans
45%
drugs
45%
genes
36%
correlations
18%
stem cells
18%
pediatrics
18%
mapping
18%
organs
9%
chemotherapy
9%
sarcomas
9%
heart failure
9%
depth
9%
in vitro
9%
tumors
9%
therapy
9%
hypothesis
9%
genotype
9%
metastases
9%
populations
9%
leukemia
9%
control
9%
data
9%
probes
9%
lymphomas
9%
solids
9%
biopsy
9%
Biochemistry, Genetics and Molecular Biology
Doxorubicin
100%
Single-Nucleotide Polymorphism
54%
Expression Quantitative Trait Loci
36%
Gene Expression
18%
Genome-Wide Association Study
18%
Induced Pluripotent Stem Cell
18%
Electric Potential
18%
Pediatrics
18%
Experience
18%
Bioinformatics
9%
Primary Cell
9%
Phenotype
9%
Candidate Gene
9%
Genotyping
9%
Drug Response
9%
CRISPR/Cas9
9%
Quantitative Trait Locus Mapping
9%
Solid
9%
Coding
9%
Association
9%
Genome Editing
9%
Probe
9%